Blueprint proposes $275M follow-on after ASH gains

Blueprint Medicines Corp. (NASDAQ:BPMC) gained $16.46 (23%) to $88.32 on Monday after reporting its lead candidate, avapritinib (formerly BLU-285), led to an overall response rate (ORR) of

Read the full 272 word article

User Sign In